INDEPENDENT NEWS

Blis confirms Asia-Pacific and Africa distribution agreement

Published: Fri 7 Sep 2018 01:51 PM
Blis Technologies confirms Asia-Pacific and Africa distribution agreement with iNova Pharmaceuticals
7 September 2018 | Dunedin, New Zealand
Blis Technologies Limited today confirmed it has entered into a distribution agreement with iNova Pharmaceuticals (Singapore) Pte Ltd for the distribution of BLIS branded products. iNova Pharmaceuticals is a multinational pharmaceutical and consumer health care company that markets and sells a wide range of market-leading products in over 20 countries across Asia-Pacific and Africa.
The agreement will provide iNova Pharmaceuticals with exclusive distribution rights for BLIS branded products across Australia, Sub-Saharan Africa, and Asia based on a commitment of resources to support product launches. iNova Pharmaceutical’s presence in pharmacy retail provides a strong platform for the launch of BLIS branded products into overseas markets.
The initial focus will be on launch plans for the Australian market where BLIS K12 has achieved inclusion in TGA’s Therapeutic Goods (Permissible Ingredients) Determination for use in listed complementary medicines, allowing stronger positioning of the BLIS portfolio.
Blis CEO Brian Watson says that this agreement is another important step in the company’s finished product strategy.
“iNova Pharmaceuticals has a strong presence in the pharmacy channel and a proven track record of establishing category-leading brands in consumer health care. Working with a partner of this calibre will provide the right capability and resourcing to effectively establish BLIS branded products in multiple markets across the iNova Pharmaceuticals network. Our focus initially will be to finalise our plans for the Australian market but also to progress launch plans for other markets across Asia and Africa”
The agreement builds on the success of Blis Technologies’ new distribution relationship in New Zealand with Radiant Health, which also holds the distribution rights for the iNova Pharmaceuticals product range locally. Radiant has demonstrated its ability to leverage its presence in the market to help grow the BLIS range.
ENDS

Next in Business, Science, and Tech

RBNZ To Implement $30bn Large Scale Asset Purchase Programme Of NZ Govt Bonds
By: The Reserve Bank of New Zealand
Monetary Policy With Very Low Interest Rates
By: The Reserve Bank of New Zealand
More Snow On Glaciers But No Good News, Say Scientists
By: NIWA
Elevate NZ Venture Fund To Lift Productivity
By: New Zealand Government
New Legislation To Boost Organics
By: New Zealand Government
Misinformation Circulating On Biodiversity Policy
By: Forest And Bird
Govt Backs RBNZ Move To Support Economy With Lower Interest Rates
By: New Zealand Government
Reserve Bank announces further measures to support economy
By: RNZ
Holding Off The COVID-19 Recession – Expert Reaction
By: Science Media Centre
Banking Sector Prepared For Responding To COVID-19
By: The Reserve Bank of New Zealand
Reserve Bank’s ‘unconventional Tools’ Are Conventional Elsewhere
By: Social Credit
RBNZ Survey: Experts Say An Out-of-cycle Rate Cut May Cause Panic
By: Finder
Next Steps Of Govt And Business COVID-19 Response
By: New Zealand Government
NZX falls following US interest rate cut
By: RNZ
Coronavirus and the economy: Responding to Covid-19 with precision
By: RNZ
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media